These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8245539)

  • 1. Congenital yellow fever virus infection after immunization in pregnancy.
    Tsai TF; Paul R; Lynberg MC; Letson GW
    J Infect Dis; 1993 Dec; 168(6):1520-3. PubMed ID: 8245539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sero-prevalence of yellow fever and related Flavi viruses in Ethiopia: a public health perspective.
    Mengesha Tsegaye M; Beyene B; Ayele W; Abebe A; Tareke I; Sall A; Yactayo S; Shibeshi ME; Staples E; Belay D; Lilay A; Alemu A; Alemu E; Kume A; H/Mariam A; Ronveaux O; Tefera M; Kassa W; Bekele Weyessa A; Jima D; Kebede A; Tayachew A
    BMC Public Health; 2018 Aug; 18(1):1011. PubMed ID: 30107830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yellow fever vaccination and pregnancy: a four-year prospective study.
    Nasidi A; Monath TP; Vandenberg J; Tomori O; Calisher CH; Hurtgen X; Munube GR; Sorungbe AO; Okafor GC; Wali S
    Trans R Soc Trop Med Hyg; 1993; 87(3):337-9. PubMed ID: 8236412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil.
    Suzano CE; Amaral E; Sato HK; Papaiordanou PM;
    Vaccine; 2006 Feb; 24(9):1421-6. PubMed ID: 16236402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of the yellow Fever vaccine: a retrospective study.
    Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
    J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
    Brandriss MW; Schlesinger JJ; Walsh EE; Briselli M
    J Gen Virol; 1986 Feb; 67 ( Pt 2)():229-34. PubMed ID: 3944585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
    Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
    J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.
    Gibney KB; Edupuganti S; Panella AJ; Kosoy OI; Delorey MJ; Lanciotti RS; Mulligan MJ; Fischer M; Staples JE
    Am J Trop Med Hyg; 2012 Dec; 87(6):1112-5. PubMed ID: 23109371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.
    Poland JD; Calisher CH; Monath TP; Downs WG; Murphy K
    Bull World Health Organ; 1981; 59(6):895-900. PubMed ID: 6978196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study.
    Nishioka Sde A; Nunes-Araújo FR; Pires WP; Silva FA; Costa HL
    Trop Med Int Health; 1998 Jan; 3(1):29-33. PubMed ID: 9484965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
    Scott RM; Eckels KH; Bancroft WH; Summers PL; McCown JM; Anderson JH; Russell PK
    J Infect Dis; 1983 Dec; 148(6):1055-60. PubMed ID: 6655288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential dengue cross-reactive and neutralizing antibody responses in BALB/c and Swiss albino mice induced by immunization with flaviviral vaccines and by infection with homotypic dengue-2 virus strains.
    Lim CS; Chua JJ; Wilkerson J; Chow VT
    Viral Immunol; 2006; 19(1):33-41. PubMed ID: 16553548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An outbreak of yellow fever with concurrent chikungunya virus transmission in South Kordofan, Sudan, 2005.
    Gould LH; Osman MS; Farnon EC; Griffith KS; Godsey MS; Karch S; Mulenda B; El Kholy A; Grandesso F; de Radiguès X; Brair ME; Briand S; El Tayeb el SM; Hayes EB; Zeller H; Perea W
    Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1247-54. PubMed ID: 18502458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection.
    Slon Campos JL; Poggianella M; Marchese S; Mossenta M; Rana J; Arnoldi F; Bestagno M; Burrone OR
    PLoS One; 2017; 12(7):e0181734. PubMed ID: 28742857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.